We also demonstrated that the new clinical compound Unesbulin, identified by its ability to kill BMI-1+ cancer cells (24), that favorably completed phase I clinical trial in patients with advanced solid tumors (24), affects lung tumor progression in Kras-mutant/p53-null mice (23). Here, KRAS is linked to cancer.